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Background
MCD is characterized by inflammatory symptoms, sple-
nomegaly, adenopathy, hypoalbuminemia, hyponatremia,
and cytopenias. MCD in HIV-infected patients is gener-
ally KSHV-associated. No standard therapy exists. Ritux-
imab has activity, but monotherapy may be insufficient
in severe disease and can be associated with worsening
of Kaposi’s sarcoma (KS).
Methods
Patients with symptomatic MCD received rituximab
375 mg/m
2 plus liposomal doxorubicin 20 mg/m
2 every
21 days until substantial clinical improvement or disease
progression. This regimen is being evaluated prospec-
tively within an MCD natural history protocol. Addi-
tional therapy, employing agents with antiviral activity
(discussed below), was generally employed to consolidate
or maintain responses. Clinical, biochemical, and radio-
graphic responses were evaluated using protocol-defined
criteria. Overall complete response (CR) required nor-
malization of all MCD-related abnormalities.
Results
Patient characteristics: 12 (1 woman, 11 men) patients
completed R-dox. Median age, 43 (34-55); median num-
ber of prior therapies 2 (0-8). Diffuse adenopathy (12);
median spleen (cm), 18.5 (12.5-28). Concurrent KS (5).
All were receiving concurrent combination antiretroviral
therapy. Baseline laboratory values, median (range): CD4
cells/μL, 291 (21-1598); C-reactive protein (mg/dL), 9.9
(0.4-21); albumin (mg/dL), 2.7 (1.5-3.3); sodium (mEq/
L), 133 (126-136); platelets (K/μL), 70 (10-377); hemo-
globin (gm/dL), 9.4 (6.8-12.2). Median cycles received
4.5 (3-9) (Table 1)
With 9 patients receiving additional therapy after
R-dox; IFNa (6), high-dose zidovudine + valganciclovir
(2), additional liposomal doxorubicin (1); 6 additional
patients achieved overall CR (total 75%). KS responded
in 4/5 (80%). With 31.4 months median potential fol-
lowup (actual 5.5+ to 47+), estimated 2-year progres-
sion-free survival and overall survival are 61.1% and
78.6%, respectively. 8/12 (67%) remain symptom free,
while 3 had recurrent MCD flares (months 7, 10, 17)
responding to additional R-Dox. One had progressive
MCD and worsening KS during cycle 6 and died at
month 6. At autopsy, primary effusion lymphoma was
discovered. One patient died at month 17 of sepsis
unrelated to therapy. Select toxicities: 9 infusion reac-
tions (Gr. 1 = 3, Gr. 2 = 4, Gr. 3 = 2) with the first dose
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Table 1 Best response with R-Dox
Response
Category
Complete
Response
Partial
Response
Stable
Disease
Clinical 12 (100%) - -
Biochemical 10 (83%) 1 (8%) 1 (8%)
Radiographic 6 (50%) 6 (50%) -
Overall 3 (25%) 6 (50%) 3(25%)
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© 2010 Uldrick et al; licensee BioMed Central Ltd.of rituximab; 6/60 cycles complicated by neutropenia
(Gr. 2 = 5, Gr. 3 = 1), no infectious complications.
Conclusions
R-Dox is effective in treating severe KSHV-MCD or
MCD with concurrent severe KS. Evaluation of R-Dox
in KSHV-MCD is ongoing.
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